Quick take: Why Mesoblast has rallied 17% in the last 5 sessions
We unpack Mesoblast’s first quarter results in under 2 minutes.
Investors continued to bid Mesoblast (MSB) higher on Monday – with the stock up 6.59% to $3.88 by noon – building on the gains the company witnessed following the release of its Q1, FY21 update last Friday.
Mesoblast share price: Understanding what drove the rally in under 2 minutes
In particular, investors look enthused by the announcement of a global license and collaboration agreement between Novartis and Mesoblast. Under this agreement, it was noted that the companies would join forces to develop, 'manufacture and commercialization of Mesoblast’s mesenchymal stromal cell (MSC) product resentence-L.'
Commenting on this partnership, Mesoblast's CEO, Dr Silviu Itescu, said 'Our collaboration with Novartis will help ensure that remestemcel-L could become available to the many patients suffering from ARDS, the principal cause of mortality in COVID-19 infection.'
Despite renewed investor confidence, MSB posted Q1 revenues of just US$1.3 million, down significantly from Q1 FY20 revenues of US$17.0 million.
Research and development and manufacturing expenses also rose during the quarter, increasing by US$6.9 million and US$9.2 million, respectively. Increased research and development costs were driven by 'increased clinical trial costs relating to the Phase 3 trial for COVID-19 ARDS, non-cash share-based payments to employees and consultants and pre-commercial activities for remestemcel-L,' the company said.
Overall, these results culminated in MSB reporting a post-tax Q1 loss of US$24.5 million.
Despite that loss, investors appear particularly pleased with the Novartis partnership; the stock, after all, was bid 16.2% higher during last Friday’s session.
Want to take a position in Mesoblast – long or short?
Create an IG trading account or log in to your existing account to get started now.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.